This document discusses post-Brexit implications for research and cooperation in Europe. It outlines how Brexit may impact the movement of staff in research and health industries, future data protection and clinical trial frameworks, and authorization of new medicines. It also summarizes several ongoing EU research initiatives on neurodegenerative diseases, including the Joint Programme for Neurodegenerative Disease Research (JPND) and Innovative Medicines Initiative (IMI), and EU Joint Actions on Dementia.